Competitive landscape
Drugs aimed at the same indication, from approved to preclinical.
1 drug for “MASH - Metabolic Dysfunction-Associated Steatohepatitis”
Phase 3 1
- EfruxiferminAkero Therapeutics, Inc.MASH - Metabolic Dysfunction-Associated Steatohepatitis
Drugs whose recorded indications name this term, by development stage. Indications come from registries and labels, so a drug can appear under related terms.